Shots:

• The approval is based on P-III HAWK (NCT02307682) & HARRIER (NCT02434328) studies involves assessing of Beovu (intravitreal injection)- 6mg (HAWK and HARRIER) & 3mg (HAWK) vs Aflibercept (2mg) in 1-800+ patients with wet AMD across 400 centers globally
• The P-III studies demonstrated non-inferiority in mean change BCVA @1yr. (week 48); reductions in central subfield thickness- @1yr. 56% & 51% maintained on the 3mos. dosing interval
• Beovu (RTH258) is the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to 3mos. dosing intervals immediately after loading phase with no compromise in efficacy

Click here to­ read full press release/ article | Ref: Novartis | Image: Financial times